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Abstract 
Background: Malaria still represents a major cause of morbidity and mortality predominantly in several developing 
countries, and remains a priority in many public health programmes. Despite the enormous gains made in control 
and prevention the development of an effective vaccine represents a persisting challenge. Although several para‑
site antigens including pre‑erythrocytic antigens and blood stage antigens have been thoroughly investigated, the 
identification of solid immune correlates of protection against infection by Plasmodium falciparum or clinical malaria 
remains a major hurdle. In this study, an immuno‑epidemiological survey was carried out between two populations 
naturally exposed to P. falciparum malaria to determine the immune correlates of protection.
Methods: Plasma samples of immune adults from two countries (Ghana and Madagascar) were tested for their 
reactivity against the merozoite surface proteins MSP1‑19, MSP3 and AMA1 by ELISA. The antigens had been selected 
on the basis of cumulative evidence of their role in anti‑malarial immunity. Additionally, reactivity against crude P. 
falciparum lysate was investigated. Purified IgG from these samples were furthermore tested in an invasion inhibition 
assay for their antiparasitic activity.
Results: Significant intra‑ and inter‑ population variation of the reactivity of the samples to the tested antigens 
were found, as well as a significant positive correlation between MSP1‑19 reactivity and invasion inhibition (p < 0.05). 
Interestingly, male donors showed a significantly higher antibody response to all tested antigens than their female 
counterparts. In vitro invasion inhibition assays comparing the purified antibodies from the donors from Ghana and 
Madagascar did not show any statistically significant difference. Although in vitro invasion inhibition increased with 
breadth of antibody response, the increase was not statistically significant.
Conclusions: The findings support the fact that the development of semi‑immunity to malaria is probably con‑
tingent on the development of antibodies to not only one, but a range of antigens and that invasion inhibition in 
immune adults may be a function of antibodies to various antigens. This supports strategies of vaccination including 
multicomponent vaccines as well as passive vaccination strategies with antibody cocktails.
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Background
Malaria is a tropical disease found in most African coun-
tries including Ghana and Madagascar, because the high 
temperature and humidity combined with the presence 
of stagnant water provide ideal breeding conditions for 
the female Anopheles mosquito, the vector. It is a leading 
cause of morbidity and mortality, particularly in children 
living in endemic regions, causing 124–283 million infec-
tions and approximately 584,000 deaths per annum with 
no signs of a significant decline [1]. In Ghana, malaria 
accounts for at least 20 % of child deaths, 40 % of admis-
sions of children to hospital and more than 50 % of out-
patients [2].
Effective malaria vaccines remain an elusive goal 
despite the availability of the Plasmodium falciparum 
genome sequence, which makes malaria one of the few 
remaining severe infectious childhood diseases without 
any efficient vaccine. This is caused by a combination of 
factors, including the multistage lifecycle of the parasite 
(each with stage-specific antigens), its genetic diversity, 
and an incomplete understanding of its immunopathol-
ogy, resulting in a lack of immunological markers corre-
lating with immunity.
Antigens expressed on the surface of asexual blood-
stage malaria parasites are major targets for antibodies 
elicited by infection. These IgG antibodies prevent mero-
zoite invasion of red blood cells, as well as opsonize para-
sitized red blood cells, and prevent cytoadherence. Thus, 
they form a major component of the defense against 
asexual blood-stage parasites and are therefore prime tar-
gets for vaccine development. Susceptibility to infection 
and episodes of disease decline in frequency and sever-
ity over time, but it is unclear which asexual blood-stage 
antigens are targets for this naturally acquired immunity. 
The most likely marker candidates include merozoite 
surface protein 1 (MSP1) and its C-terminal product, 
(MSP1–19), apical membrane antigen 1 (AMA1) and 
merozoite surface protein 3 (MSP3), reflecting cumula-
tive evidence of their role in naturally-acquired immunity 
to malaria based on epidemiological studies in countries 
such as Myanmar [3], Tanzania [4], Ghana [5–7], Kenya 
[8], Mali [9] and Venezuela [10].
MSP1 is a large protein which is proteolytically pro-
cessed into the subunits MSP1-83, MSP1-30, MSP1-38 
and MSP1-42 [11–13]. The MSP1-42 fragment is pro-
cessed in a further step into MSP1-19 and MSP1-33 dur-
ing erythrocyte invasion, leaving only the C-terminal 
cleaving product MSP1-19 bound on the surface of the 
pathogen by a GPI-anchor.
AMA1 appears on the surface of merozoites when 
released from the micronemes and undergoes processing 
from an 83-kDa precursor into a 66-kDa mature protein 
that is also known to play an essential role in erythrocyte 
invasion, forming the tight junction with the protein 
Ron2L [14]. During invasion the surface protein AMA1-
66 is further processed and AMA1-48 as well as AMA1-
44 are released into the blood stream [15–17]. For the 
processing of both proteins MSP-1 and AMA1, the pro-
tein subtilisin-like protease 2 (SUB2, sheddase) is respon-
sible [18].
Many individuals with naturally acquired immunity 
to malaria produce anti-MSP1-19 and anti-AMA1-66 
antibodies that play a critical role in their immunity by 
inhibiting erythrocyte entry. There is a strong correlation 
between these antibody titers and the levels of protection 
against malaria in endemic regions [19].
MSP3 is a 48-kDa protein found on the surface of mer-
ozoites, which unlike the other candidates, was identified 
by studying the monocyte-dependent parasite-inhibition 
effect observed following the passive transfer of IgG 
from immune African adults into infected Thai children 
[20]. Epidemiological studies confirmed that protection 
is associated with cytophilic responses against MSP3 [3, 
21–23].
The present study profiled the immune response to 
MSP1-19, AMA1 and MSP3 within and between two 
diverse populations, in the malaria-endemic regions of 
Ghana and Madagascar, focusing on the ability of plasma 
from such individuals to inhibit erythrocyte invasion.
Methods
Study design/study population and blood sample 
collection
Blood samples from a voluntary study population, ran-
domly recruited in the local communities residing in 
Kumasi (Ghana) and Mahajanga (Madagascar) were 
taken in February and March 2010 (for Ghana) and Janu-
ary 2010 (for Madagascar). These time points correspond 
to the beginning of the rainy season in Ghana and the 
peak of the rainy season in Madagascar. Malaria trans-
mission in Ghana is stable throughout the year and sea-
sonal in Madagascar, with peak transmission during the 
rainy season [24, 25]. A total of 136 adults comprising 
73 females and 63 males aged between 25 and 49  years 
were enrolled in this population-based cross-sectional 
immuno-epidemiological study. Basic information was 
gained after anamnesis and physical examination. Only 
healthy individuals who had been without self-reported 
clinical signs of malaria infection for at least 2  years in 
Ghana and at least 5  years in Madagascar were eligible 
for the study. Additionally, only people staying for the 
given time either in Ghana or Madagascar were admit-
ted to the study. No pregnant or nursing mother, or indi-
vidual with a known inflammatory condition or anemia, 
based on a general physical examination and a complete 
blood count at the time of blood collection, was included 
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in the study. Written informed consent was obtained 
from all participants after the goals of the study had been 
carefully explained. Study participants were remunerated 
for the travel expenses to and from the study site. Ethical 
approval was obtained from the Committee on Human 
Research Publication and Ethics (CHRPE) of the Kwame 
Nkrumah University of Science and Technology and the 
National Ethics Committee of the Ministry of Health and 
Family Planning of Madagascar. Blood was collected into 
heparinized vacutainers, the plasma was prepared and 
stored at −20 °C.
Antigens
Four different kinds of antigen preparations were used 
during the study. For measurement of reactivity against 
the AMA1 antigen, a mixture of the diversity covering 
variants (DiCo1-3) were used [26]. MSP1-19 (sequence 
from P. falciparum 3D7, PlasmoDB, #Pf3D7_090300, 
amino acids 1608-1702) was produced in HEK293T in 
a construct containing a murine Igκ signal peptide for 
protein secretion and a C-terminal His6-tag for protein 
purification by immobilized metal affinity chromatog-
raphy (IMAC), basically as described before [27]. Two 
N-P-S/T motives had been mutated in order to prevent 
N-glycosylation. MSP3 (sequence from P. falciparum 
3D7, PlasmoDB #Pf3D7_1035400, amino acids 25-354) 
was produced in tobacco plants (Nicotiana benthamiana) 
using a construct containing a murine IgG heavy chain 
signal peptide for protein secretion, a C-terminal His6-tag 
for protein purification by IMAC and C-terminal KDEL 
for retention in the ER as described before [28]. Four 
potential glycosylation sites had been removed by replac-
ing the respective Asn by Ala. Lysates from P. falciparum 
3D7 cultures were prepared as described before [29].
Enzyme‑linked immunosorbent assays
The plasma samples from the African blood donors, 
as well as a pool of two plasma samples from European 
blood donors, were analysed by enzyme-linked immu-
nosorbent assay (ELISA) to detect IgGs specific for the 
recombinant malaria proteins AMA1, MSP1-19 and 
MSP3, as well as general reactivity against the P. falcipa-
rum lysate, similar to the methods described before with 
minor modifications [30]. Microtitre plates were coated 
with 50 ng of the recombinant proteins diluted to 1 μg/ml 
in phosphate-buffered saline (PBS) at pH 7.4. After incu-
bation overnight at 4  °C, the plates were washed three 
times with PBS containing 0.05 % Tween-20 (PBST) and 
blocked with 2 % nonfat milk powder in PBS for 1 h at 
37 °C. African serum dilutions from 1:200 to 1:6400 were 
prepared, and incubated for 1 h at 37 °C.
The plates were washed three times with PBST and 
bound IgG was detected with alkaline phosphatase 
conjugated goat anti-human IgG (1:5000 dilution in PBS, 
Thermo Scientific, Braunschweig, Germany) for 1  h at 
37  °C. After five washing steps in PBST, the signal was 
developed using the substrate p-nitrophenyl phosphate 
(pNPP). Absorbance of the samples was recorded at 
405 nm after 15 min.
Quantitative evaluation of the ELISA results were per-
formed by calculation of the slopes of the linear range of 
the graphs obtained by the dilution vs the obtained absorb-
ance. Values given are relative activity whereby the back-
ground reactivity of the non-immune European donor is 
equal to one. Positive reactivity was defined as reactivity 
superior to the European sample plus twice its standard 
deviation (SD). To account for the inter-plate variances, a 
pool of positive samples was used on each plate.
Protein A affinity chromatography of plasma samples
To prevent nonspecific inhibition from heparin and other 
plasma components, the human antibodies were puri-
fied by Protein A affinity chromatography and tested for 
efficacy in invasion inhibition assays. Each 300 μl plasma 
sample was diluted such as to obtain 1  ml in PBS (pH 
8.0) and passed over an equilibrated Protein A column 
by gravity flow. The flow-through was discarded and the 
column was washed with 35 column volumes of wash 
buffer. The antibodies were eluted in five column volumes 
of 0.1 M glycine (pH 2.5) and collected into 200 μl of 1 M 
Tris–HCl (pH 8.0) to neutralize the eluate and prevent 
denaturation. The eluates were concentrated to obtain 
the original antibody concentration by centrifugation 
at 300g for 15 min in MicroSep columns (Pall, Dreieich, 
Germany) and the concentrates were sterile filtered and 
subsequently used in the erythrocyte invasion inhibi-
tion assay after concentration determination by Bradford 
analysis and confirmation of integrity by SDS-PAGE.
Invasion inhibition assay
Plasmodium falciparum 3D7 parasites were cultured in 
standardized parasite culture medium (RPMI 1640, 0.5 % 
Albumax II (Life Technologies, Carlsbad, CA, USA), 
sodium bicarbonate 1  g/l, glucose 2  g/l, hypoxanthine 
0.028  g/l, gentamycin 0.2  g/l, pH 7.2) and synchronized 
using the sorbitol method twice at ring stage during two 
consecutive cycles, the last one 24  h before starting the 
assay, as described before [30]. Protein A-purified IgG 
fractions (final dilution 1:10, final concentration approx. 
0.5 mg/ml), positive control rabbit anti-AMA1 (final con-
centration 6 mg/ml) were applied to synchronized P. falci-
parum schizonts (parasitaemia of 0.1 %/final haematocrit 
5  %/total volume 50  µl) in 96-well round bottom plates. 
Cultures were kept at 37 °C for 96 h (two complete eryth-
rocyte cycles). After this incubation time, parasite cultures 
were stained for 10 min using 0.1 % ethidium bromide, and 
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subsequently analysed by flow cytometry using a BDFAC-
SCanto II (BD Biosciences, Heidelberg, Germany).
Statistical analysis
The results are presented as mean  ±  SD for normally 
distributed data and as means and 95  % Confidence 
Intervals (95  % CI) for non-normally distributed data. 
Comparisons were performed using the Kruskal–Wallis 
ANOVA tests and Dunn’s post-tests for selected multiple 
comparisons. In cases of comparison of two populations, 
Mann–Whitney U rank test was performed. Categori-
cal data were analysed using Fisher’s exact test or χ2 (Chi 
squared) trend analysis. Spearman’s Rank Correlation 
Coefficient (rho) was used to test for the degree of asso-
ciation between test parameters. A p value of < 0.05 was 
considered to be statistically significant. P-values in fig-
ures are represented by asterisks (*, p < 0.05; **, p < 0.01; 
***, p < 0.001; ****, p < 0.0001) All statistical analyses were 
carried out using GraphPad Prism v6.07 for Windows 
(GraphPad Software, San Diego, CA, USA).
Results
General characteristics of the study population stratified 
by country and gender
Among the 136 participants selected in this study, 
78 (57.4  %) were from Ghana and 58 (42.6  %) were 
from Madagascar. Approximately half (46.3  %) of the 
studied population were males, with a mean age of 
31.9 ± 6.6 years, which was lower than that of the total 
study population (33.6  ±  6.8  years). The mean age of 
the females in the study was 35.1 ±  6.8  years. The par-
ticipants from Ghana were younger (p  <  0.0001) com-
pared to their Malagasy counterparts. A similar trend 
(p = 0.007) was observed when the male study subjects 
were compared to their female counterparts.
The mean reactivity of the samples was highest against 
the 3D7 lysate followed by AMA1 and then MSP3, and 
lowest in MSP1-19. The same trend was observed when 
the study population was stratified by country and by 
gender (Fig. 1).
The mean reactivity and 95 % CI of the total study pop-
ulation against AMA1 was 1.7 (95 % CI: 1.3–2.2) (Fig. 1a). 
This was lower than the mean reactivity of the Ghanaian 
subjects 2.4 (95  % CI: 1.7–3.1) but higher than the one 
for the Malagasy subjects [0.8 (95 % CI: 0.4–1.2)], which 
means that the Ghanaian subjects showed a significantly 
higher reactivity to AMA1 than the Malagasy subjects 
(p < 0.0001). The mean reactivity of the male subjects in 
the study [2.4 (95 % CI: 1.6–3.3)] was significantly higher 
(p  =  0.0012) than the one of the female subjects [1.1 
(95 % CI: 0.8–1.5)].
Figure 1b, c and d show similar results for the other tar-
gets. The mean reactivity of the Ghanaian subjects was 
significantly higher than that of the Malagasy donors for 
MSP1-19 1.2 (95 % CI: 0.7–1.3) vs 0.5 (95 % CI: 0.2–0.9), 
(p < 0.0001), MSP3 1.6 (95 % CI: 0.9–1.5) vs 0.6 (95 % CI: 
0.4–0.9) (p < 0.0001) and 3D7 lysate 4.5 (95 % CI: 3.8–5.3) 
vs 2.3 (95 % CI: 1.3–3.3) (p < 0.0001). The mean reactiv-
ity of the male subjects was also significantly higher than 
that of the female subjects for MSP1-19 1.3 (95  % CI: 
0.8–1.7) vs 0.6 (95 % CI: 0.4–0.7) (p = 0.0442), MSP3 1.6 
(95 % CI: 1.2–2.0) vs 0.8 (95 % CI: 0.6–1.1) (p = 0.0063) 
and 3D7 lysate 4.4 (95 % CI: 3.5–5.3) vs 2.9 (95 % CI: 2.0–
3.7) (p = 0.0006).
Antibody prevalence stratified by country and gender
As shown in Fig. 2, antibodies against the 3D7 lysate were 
detected in 94 of the 136 subjects and were therefore the 
most prevalent (69.1 %). Antibodies against AMA1 were 
detected in 66 subjects (48.5 %), those against MSP3 were 
detected in 50 subjects (36.8 %) and those against MSP1-
19 were found in 29 subjects (21.3 %). The Ghanaian sub-
jects generally showed greater antibody prevalence than 
the Malagasy donors, and males showed greater antibody 
prevalence than the females (Fig. 2 and Table 1).
Invasion inhibition results stratified by country and gender
The invasion inhibition was estimated in  vitro. The 
inhibitory effect of a positive control (rabbit anti-AMA1 
polyclonal serum) was 84.8 ±  2  %. In the human study 
samples, despite the clear differences in antibody preva-
lence and reactivity, there was no significant difference 
in the efficacy of erythrocyte invasion inhibition when 
the study population was stratified by country and gen-
der (Fig.  3). The median invasion inhibition was higher 
in the Ghanaians than in the Malagasy; these differences 
were, however, not statistically significant (Fig.  3a). It is 
interesting to note that although the male population 
showed a statistically significant higher antigen reactivity 
and prevalence over the females, there was no difference 
in invasion inhibition activity. When the participants 
were stratified by country and gender simultaneously to 
produce four comparative groups, there was again no 
statistically significant difference in the median invasion 
inhibition between Ghanaian males and females, and 
between Malagasy males and females (Fig. 3b).
Correlation between reactivity and invasion inhibition
Figure 4 shows a linear regression of reactivity and eryth-
rocyte invasion inhibition for each antigen, which was 
carried out to test the use of reactivity to predict invasion 
inhibition efficacy. To test for the correlation of both var-
iables, Spearman’s Rank Correlation Coefficient test was 
used. For every unit increase in MSP1-19 reactivity there 
was a significant increase of 57 % in erythrocyte invasion 
inhibition (p = 0.0308). For the other antigens, there was 
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no correlation with the invasion inhibition tests detect-
able. All samples with a reactivity superior to 2 showed 
at least an in vitro invasion inhibition of 50 % (Fig. 4b). 
For the other antigens tested, no correlation of the cor-
responding reactivity in the tested samples and the 
potential to inhibit the invasion could be detected. The 
corresponding data and p values are shown in Fig. 4a, c 
and d.
Invasion inhibition and breadth of the antibody response
A Kruskal–Wallis test with a Dunn’s post test showed a 
gradual increase in the efficacy of erythrocyte invasion 
inhibition as the breadth of antibody response broadened 
(Fig. 5) although the trend was not statistically significant 
(p = 0.1444).
Discussion
This population-based cross-sectional immuno-epidemi-
ological study profiled the immune response to MSP1-19, 
AMA1, MSP3 and the P. falciparum 3D7 lysate within 
and between two diverse malaria endemic populations 
in Ghana and Madagascar with focus on the ability of 
plasma from such individuals to inhibit erythrocyte inva-
sion. In this study, immune correlates of protection in 
two endemic regions were compared, in order to provide 
the basis for the distribution of the most antigen-specific 
Fig. 1 Antigen reactivity of plasma samples from the Ghanaian and Malagasy study population. Plasma samples were collected from 136 Ghanaian 
and Malagasy volunteers, and the respective reactivity towards the malarial antigens AMA‑1 (a), MSP1‑19 (b), MSP3 (c) and total 3D7 parasite lysate 
(d) quantified using standard ELISA towards 50 ng coated antigen each. As negative control, a pool of plasma samples from malaria‑naïve European 
volunteers was used (dashed line). Sample reactivity was quantified after addition of goat anti‑human IgG antibody (Thermo Scientific) at a dilution 
of 1:5000 and subsequent addition of pNPP. The arbitrary units on the y-axis are the sample reactivity divided by the reactivity of the negative 
control. For statistical analysis of the populations, the non‑parametric Kruskal–Wallis and Dunn’s post test was used, asterisks indicate the level of 
statistical significance
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immune responses in these areas. These study objec-
tives were achieved by using ELISAs to measure total IgG 
antibody responses to MSP1-19, AMA1, MSP3 and the 
P. falciparum 3D7 lysate in the stratified study popula-
tion. The prevalence of the antibodies was determined, 
and correlations between antibody reactivity, preva-
lence and erythrocyte invasion inhibition efficacy were 
investigated.
The relationship between the mean reactivity to MSP1-
19, MSP3 and the 3D7 lysate antigens and age has been 
established in several studies [31–33]. However, most 
of these studies were done in infants, children and ado-
lescents, whereas the present study focused on peo-
ple with fully developed protective immune responses. 
This notwithstanding, the observations made in this 
study corroborate the findings of the earlier studies. On 
the other hand, the prevalence of antibodies was higher 
in Ghanaian males compared to Ghanaian females for 
both antibodies to MSP3 and to 3D7 lysate, in contrast 
to observations made elsewhere [10]. Nevertheless, this 
did not have an effect on the inhibitory potential of the 
purified polyclonal antibodies from these donors, giving 
Fig. 2 Prevalence of antibodies in plasma samples from the Ghanaian and Malagasy study population recognizing antigens a AMA1, b MSP1‑19, 
c MSP3 and d 3D7 lysate stratified by country and gender. The antibody titers of the plasma samples were determined by ELISA. Positive reactivity 
was defined as reactivity higher than the respective negative control plus two times the value of the standard deviation of the negative control. Dif‑
ferences in the antibody prevalence were estimated by the Fisher’s exact test and in case of statistical significance corresponding p values are given
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a hint that the quantity of functional, (in vitro) neutraliz-
ing antibodies in both populations is similar. It is under 
debate whether the in vitro assays give a real hint for pro-
tection from clinical malaria in an epidemiological set-
ting. Whereas Marsh et al. [34] did not find any relation 
of invasion inhibition and protection, Crompton et al. saw 
a significantly reduced risk of having a malaria attack in 
people with high in vitro invasion inhibition activity [35].
The reactivity of the samples to the three antigens 
(MSP1-19, AMA1 and MSP3) and one antigen mixture 
(3D7 lysate) considered in this study was related to the 
gender and ethnicity of the participants. This appears to 
be the first time in which all these antigens were exam-
ined in a single study to define the immune response in 
adults from malaria-endemic areas. Whereas Ghanaian 
men showed higher reactivity to all antigens in com-
parison to the Malagasy counterparts, Ghanaian women 
showed higher levels of reactivity against AMA1, MSP1-
19 and 3D7 lysate compared to the Malagasy female 
counterparts (Table 1).
The variation in reactivity observed among the indi-
viduals may reflect a number of underlying factors, such 
as different exposure levels and transmission intensities 
across the study areas, the difference in the minimal time 
period since the last clinical malaria infection as reported 
during the recruitment, differences in host genetic fac-
tors, and differences in the predominant parasite strains 
in the tested areas. With regard to endemicity, Kumasi 
(Ashanti region, Ghana) represents a holoendemic 
region with year-round malaria transmission, whereas 
Mahajanga (Boeny region, Madagascar) is meso- to 
hyperendemic with a seasonal transmission pattern [36, 
37]. The presence of other infectious diseases, whose epi-
demiology may be regional or gender-biased, may also 
prevent the development of antibodies against malarial 
antigens. There may also be erythrocytic heterogeneity 
among the stratified populations, resulting in the selec-
tion of particular parasite ligands that can mediate suc-
cessful invasion [38].
A significant positive correlation between reactivity to 
MSP1-19 and invasion inhibition could be observed in the 
presented study, as well as a positive relationship between 
AMA1 and MSP3 reactivity and invasion inhibition albeit 
below the threshold of statistical significance. The clinical 
relevance for the specific in vitro invasion inhibition effect 
of antibodies which are specific for MSP1-19 and their 
protective effect from malaria infection has been reported 
before for a cohort from a highly endemic area in Kenya 
[39]. In this study, the upper quartile of donors had a sig-
nificant protection from reinfection with the observation 
period of 10  weeks after parasite clearance. Neverthe-
less, they could not find a direct correlation of the total 
amounts of MSP1-19 antibodies and the concentration of 
inhibitory antibodies, which might be due to a high con-
centration of antibodies binding epitopes which are not or 
less relevant for direct invasion inhibition.
The mechanism of how AMA1 antibodies protect from 
malaria are regarded as similar to the protection offered 
by MSP1-19 antibodies. Both antibody types are capa-
ble of inhibiting the merozoite invasion directly by steric 
hindrance [40–42].
MSP3-specific antibodies are also described as being 
capable of inhibiting the invasion of merozoites into the 
erythrocytes directly [33, 43]. Generally, however, the 
Table 1 Reactivity to AMA1, MSP1-19, MSP3 and 3D7 lysate stratified by country and gender
Continuous data are presented as mean ± SD for the age and as means with 95 % confidence interval for the antigens reactivity and analyzed using the Kruskal–Wallis 
rank sum test and Dunn’s post test. Categorical data are presented as proportions and analyzed using a Chi square test
Ghana Madagascar Kuskal–Wallis Dunn‘s post test
Female (A) Male (B) Female (C) Male (D) p (A vs. B) p (C vs. D) P (A vs. C) P (B vs. D)
Age (years, ± SD) 32.2 ± 7.4 29.2 ± 4.7 37.5 ± 5.1 38.7 ± 5.7 <0.0001 0.1617 >0.9999 0.001 <0.0001
AMA1 (AU) 1.6 (1.2–1.9) 3.0 (1.9–4.2) 0.7 (0.1–1.3) 0.9 (0.4–1.4) <0.0001 0.5952 0.2926 <0.0001 0.0011
MSP1‑19 (AU) 0.7 (0.5–1.0) 1.5 (0.9–2.0) 0.7 (0.0–1.4) 0.8 (−0.3–1.9) 0.0002 0.3937 >0.9999 0.0294 0.0043
MSP3 (AU) 1.0 (0.5–1.4) 2.0 (1.5–2.6) 1.0 (0.3–1.7) 0.9 (−0.2–2.1) <0.0001 0.0141 >0.9999 0.2725 0.0002
3D7 lysate (AU) 3.5 (2.6–4.4) 5.2 (4.1–6.3) 2.3 (0.9–3.7) 2.4 (1.1–3.7) <0.0001 0.0423 0.701 0.003 0.0005
Prevalence of antibodies to the variant antigens (%) Chi square test
N 33 45 40 18 p (A vs. B) p (C vs. D) p (A vs. C) p (B vs. D)
AMA1 21 (63.6) 34 (75.6) 5 (12.5) 7 (38.9) 0.2541 0.0217 <0.0001 0.0058
MSP1‑19 6 (18.2) 17 (37.8) 4 (10.0) 2 (11.1) 0.0608 0.8977 0.3116 0.0372
MSP3 11 (33.3) 28 (62.2) 9 (22.5) 3 (16.7) 0.0117 0.6119 0.3017 0.0011
3D7 lysate 27 (81.8) 44 (87.8) 14 (35) 9 (50.0) 0.0148 0.2800 <0.0001 <0.0001
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mechanism of how MSP3-antibodies contribute to pro-
tection is regarded as being based on ADCI [30]. The 
purified human antibody fractions used in this study 
were polyclonal IgG likely directed at a whole spectrum 
of plasmodial antigens—as well as antigens completely 
unrelated to Plasmodium. Therefore, in order to pinpoint 
any effect of MSP3-specific IgG, it would be worth test-
ing just this fraction of IgG of the semi-immune donors. 
In this study, this could not be performed due to the lim-
ited availability of plasma volume per sample.
The selection of the study population was based on the 
absence of a clinical malaria infection for at least 2  years. 
Immunity to malaria is thought to be short-lived, never-
theless, continuous exposure steadily boosts the immune 
response [44]. One explanation of the difference of anti-
body titers in male and female study participants could 
be a predicted difference in the respective entomological 
inoculation rates (EIR), but at least within the first year of 
life, some differences in the EIR just seem to have a limited 
effect on the antibody levels [45]. Within the first 2 years, 
children with lower exposure were found to have higher 
malaria-specific antibody levels, even though this relation-
ship decreased with age [46]. The tendency for more males 
than females to congregate at night in many African com-
munities due to cultural reasons might also explain the 
higher mean reactivity of the males in the study population. 
A study in Madagascar also found the interesting result that 
the incidence of malaria attacks during the high transmis-
sion season was higher in males than in females, giving a 
hint that they are more often infected and therefore might 
show higher parasite-specific antibody levels over time [25].
Despite the differences we found in polyclonal plasma 
IgG reactivity against AMA1, MSP1-19 and MSP3, a gen-
der-related difference in the efficacy of invasion inhibi-
tion in vitro was not found in this study. The main aspect 
to consider here is that inhibition is likely brought about 
by a vast spectrum of different immunoglobulins—some 
of whose targets are yet to be identified—and not exclu-
sively by AMA1-, MSP1-19- or MSP3-specific antibod-
ies. Possibly, in women the protective antibody spectrum 
does differ as compared to men, but still unfolds the same 
inhibitory efficacy, at least in the in vitro assays.
A technical aspect of the measurement of the invasion 
inhibition is the potential loss of some subclass of IgG3 
by the purification of the immunoglobulins by protein A 
chromatography. This might become especially impor-
tant, when measuring the ADCI using monocytes, as 
here, IgG3 seems to play a crucial role [21].
Studies such as the one presented are the essential basis 
for the characterization of different populations in order 
to define the best qualified groups of individual donors for 
the isolation of human antibodies [28, 30]. Further stud-
ies should address (1) the effect of polyclonal IgG directed 
at one plasmodial antigen only, e.g., MSP3-specific IgG; 
(2) the incorporation of more plasmodial antigens in the 
analysis, e.g., PfRh4, PfRh5 or Ron2, the ligand of AMA1; 
(3) the effect of anti-plasmodial IgG besides mere binding, 
e.g., by incorporating immune effector cells such as neutro-
philic granulocytes to assess secondary functions [29]. The 
immune response to the various antigens is relatively het-
erogeneous, indicating that in order to provide broad pro-
tection against the malaria infection; a vaccine should cover 
multiple malarial antigens.
Fig. 3 Box‑plots of percentage invasion inhibition, stratified by 
country and gender. The invasion inhibition potential was estimated 
by a standard invasion inhibition assay using Plasmodium falcipa-
rum strain 3D7 and readout by flow cytometry after staining of the 
parasites with ethidium bromide. Groups were compared using non‑
parametric Kruskal–Wallis test. There was no statistically significant 
difference between the median invasion inhibition of the Ghanaians 
in comparison to the Malagasy, and the males in comparison to the 
females. The lower and upper margins of the box represent the 25th 
and 75th percentiles, and the extended arms represent the 10th and 
90th percentiles. The median is shown as the horizontal line within 
each box
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Conclusion
There is inter-population and inter-individual variation 
in the response of plasma samples to the malaria antigens 
tested. This is the first report of tests that (1) involves 
these selected antigens for the characterization of anti-
body levels in adults in two malaria endemic regions, and 
that (2) stratifies the study subjects on the basis of gen-
der and geography; these may have implications on the 
design and distribution of a malaria vaccine.
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Fig. 4 Linear regression between reactivity to the malarial antigens AMA1, MSP1‑19, MSP3 and 3D7 lysate and erythrocyte invasion inhibition. Inva‑
sion inhibition activities of the antibodies, as well as specific antibody concentration in the plasma samples were estimated. The correlation of the 
data sets was estimated using the Spearman’s Rank Correlation Coefficient. The data shown represent the correlation of the invasion inhibition and 
a the concentration of AMA1‑specific antibodies, b the concentration of MSP1‑19‑specific antibodies, c the concentration of MSP3‑specific antibod‑
ies and d the concentration of 3D7 lysate‑specific antibodies. The lines are the result of a linear fitting. 95 % confidence intervals of the linear fitting 
model are shown. Respective p values are given
Fig. 5 Relationship between invasion inhibition and the breadth of 
the antibody response in the Ghanaian and Malagasy study population. 
The breadth of the antibody response towards the antigens AMA1, 
MSP1‑19, MSP3 and 3D7 lysate, each defined as a reactivity superior of 
more than two standard deviations above the negative control, was 
determined. To test for the dependence of the invasion inhibition on 
the breadth of antibody response, a Kruskal–Wallis test was performed
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